Sept 13 (Reuters) - AzurRx BioPharma Inc :
* AZURRX BIOPHARMA ANNOUNCES ACQUISITION OF FIRST WAVE BIO AND ITS PROPRIETARY NICLOSAMIDE FORMULATIONS TARGETING MULTI-BILLION DOLLAR INFLAMMATORY BOWEL DISEASE INDICATIONS
* AZURRX BIOPHARMA INC - AZURRX BIOPHARMA TO BE RENAMED "FIRST WAVE BIOPHARMA" AND TRADE UNDER NEW NASDAQ TICKER SYMBOL, "FWBI"
* AZURRX BIOPHARMA INC - THREE IBD CLINICAL INDICATIONS ADDED TO GI THERAPEUTIC PIPELINE WITH MULTIPLE NEAR-TERM INFLECTION POINTS
* AZURRX BIOPHARMA INC - ENTERED A DEFINITIVE AGREEMENT TO ACQUIRE FIRST WAVE BIO INC IN STOCK AND CASH TRANSACTION VALUED AT $229 MILLION
* AZURRX BIOPHARMA INC - TRANSACTION IS BEING EFFECTED VIA A REVERSE TRIANGULAR MERGER
* AZURRX BIOPHARMA INC - AZURRX'S MANAGEMENT TEAM, INCLUDING JAMES SAPIRSTEIN, WILL CONTINUE TO LEAD RENAMED COMPANY
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.